ZEN-3219 is primarily utilized in the field of oncology as a targeted therapeutic agent. It functions as a selective inhibitor of certain enzymes or proteins that are crucial for the survival and proliferation of cancer cells. By disrupting these specific pathways, ZEN-3219 effectively halts the growth of tumors and can induce apoptosis in malignant cells. This makes it a promising candidate for the treatment of various cancers, particularly those that are resistant to conventional therapies. Additionally, ZEN-3219 is being investigated for its potential to enhance the efficacy of other cancer treatments when used in combination therapies. Its targeted approach minimizes damage to healthy cells, thereby reducing the side effects commonly associated with traditional chemotherapy. Ongoing clinical trials are focused on determining its safety, optimal dosing, and effectiveness in different cancer types.